COMMUNIQUÉS West-GlobeNewswire

Transactions of Managers and Closely Associated Persons
06/01/2026
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in [...]
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the launch of a public offering of common shares in the capital of the [...]
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
06/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program
06/01/2026
TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics , a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long COVID, today [...]
Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium
06/01/2026
PRINCETON, N. J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive [...]
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
06/01/2026
Newly added funding closes critical gap and enables planned trial initiation in early 2026 GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr [...]
Transparency Notification from Shareholders
06/01/2026
Ghent, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders PRESS RELEASE REGULATED INFORMATION 6 January 2026, 6:00 pm CET Ghent, Belgium – 6 January 2026 – Sequana Medical NV ( [...]
Ipsen - Bilan semestriel - 31 12 2025
06/01/2026
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF PARIS, FRANCE, 06 JANVIER 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui qu’au titre du contrat de liquidité confié par IPSEN S.A [...]
Ipsen – Half year statement – 2025 12 31
06/01/2026
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 06 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS [...]
Clinical Neurology Specialists Partnering with Leading International Nonprofit to Accelerate Alzheimer’s Research in Las Vegas
06/01/2026
Collaboration to Improve Access to Study for Alzheimer’s Disease LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Today, Global Alzheimer’s Platform Foundation ® (GAP) and Clinical Neurology Specialists (CNS) announced [...]
GENFIT : Profil de sécurité favorable en Phase 1 et forte activité anti-inflammatoire pour G1090N, actif clé dans l’ACLF
06/01/2026
Les résultats de Phase 1 confirment que le candidat-médicament expérimental G1090N présente un profil de sécurité et de tolérabilité favorable, justifiant la poursuite de son évaluation clinique Une activité anti- [...]
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
06/01/2026
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluation Compelling anti-inflammatory activity of G1090N was evidenced through [...]
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
06/01/2026
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of [...]
Picard Medical to Begin Rollout of FDA-Cleared Accessory for its SynCardia Total Artificial Heart
06/01/2026
The new component is designed to enhance comfort for patients as well as further reinforce the safety and reliability of the device TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: [...]
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
06/01/2026
Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular [...]
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes
06/01/2026
Clofutriben is a novel, once-daily, oral HSD-1 inhibitor that reduces excess intracellular cortisol, a new precision approach to a common underlying driver of metabolic dysfunction PORTLAND, Ore., Jan. 06, 2026 (GLOBE [...]
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer
06/01/2026
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T™, an in situ platform combination [...]

Pages